New oral anticoagulants
Journal of the Korean Medical Association
;
: 57-61, 2013.
Artigo
em Coreano
| WPRIM
| ID: wpr-86375
ABSTRACT
The most important and widely-prescribed drug for anticoagulation is a vitamin K antagonist such as warfarin although it has several limitations in clinical use. New oral anticoagulants (NOACs) have been developed to overcome these problems. The clinical efficacy and safety of dabigatran, rivaroxaban, and apixaban have been shown to be superior to warfarin through large-scale clinical trials. These NOACs can replace warfarin in significant proportions of patients with non-valvular atrial fibrillation to prevent stroke. Recent management guidelines for atrial fibrillation have already recommended NOACs for stroke prevention instead of warfarin. Future clinical studies should resolve the limitations of NOACs and try to extend their clinical indications.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pirazóis
/
Piridonas
/
Fibrilação Atrial
/
Tiofenos
/
Vitamina K
/
Varfarina
/
Benzimidazóis
/
Morfolinas
/
Beta-Alanina
/
Acidente Vascular Cerebral
Tipo de estudo:
Guia de Prática Clínica
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Medical Association
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS